Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The "COG8-PDF readthrough" protein originates from a rare mRNA processing event in certain mammals (e.g., primates and rodents), where the usual separation between the COG8 and PDF genes is lost due to evolutionary changes in splice donor and acceptor sites. This produces a transcript that spans the end of COG8 through the beginning of PDF, which may result in a protein product containing sequences from both genes[2]. There is no evidence that this fusion or readthrough protein acquires new enzymatic, receptor, or transport functions, nor is it studied as a drug target or clinical biomarker. The protein is not widely referenced in therapeutic contexts or disease association databases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Component of oligomeric Golgi complex 8-peptide deformylase readthrough protein.